scholarly journals Altered Impedance of Ear Acupuncture Point MT2 in Breast Cancer Patients: A Preliminary Observation

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Yine Hu ◽  
Huayuan Yang ◽  
Pin Wang ◽  
Tangyi Liu ◽  
Wenchao Tang
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Acupuncture Point ◽  
Preliminary Observation ◽  
Ear Acupuncture ◽  
Skin Impedance ◽  
Acupuncture Points ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Healthy Humans

Skin impedance at acupuncture points (APs) has been used as a diagnostic aid for more than 50 years. In this study, we have a diagnostic tool (JXT-2008) to measure the skin impedance of ear APs of 30 breast cancer patients and the corresponding skin impedance of ear APs of 30 healthy humans, and then we compared these changes in ear AP impedance in breast cancer patients and healthy individuals.

scholarly journals Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients

2016 ◽  
Vol 62 (7) ◽  
pp. 1002-1011 ◽  
Author(s):  
Athina Markou ◽  
Martha Zavridou ◽  
Ioanna Sourvinou ◽  
George Yousef ◽  
Sofia Kounelis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Peripheral Blood ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Primary Tumors ◽  
Expression Levels ◽  
Breast Tissues

Abstract BACKGROUND Circulating tumor cells (CTCs) and microRNAs (miRNAs) are important in liquid biopsies in which peripheral blood is used to characterize the evolution of solid tumors. We evaluated the expression levels of miR-21, miR-146a, miR-200c, and miR-210 in CTCs of breast cancer patients with verified metastasis and compared their expression levels in corresponding plasma and primary tumors. METHODS Expression levels of the miRNAs were quantified by quantitative reverse transcription PCR (RT-qPCR) in (a) 89 primary breast tumors and 30 noncancerous breast tissues and (b) CTCs and corresponding plasma of 55 patients with metastatic breast cancer and 20 healthy donors. For 30 of these patients, CTCs, corresponding plasma, and primary tumor tissues were available. RESULTS In formalin-fixed, paraffin-embedded tissues, these miRNAs were differentially expressed between primary breast tumors and noncancerous breast tissues. miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed. In multivariate analysis, miR-146a overexpression was significantly [hazard ratio 2.969 (1.231–7.157), P = 0.015] associated with progression-free survival. In peripheral blood, all miRNAs studied were overexpressed in both CTC and corresponding plasma. There was a significant association between miR-21 expression levels in CTCs and plasma for 36 of 55 samples (P = 0.008). In plasma, ROC curve analysis revealed that miR-21, miR-146a, and miR-210 could discriminate patients from healthy individuals. CONCLUSIONS Metastasis-related miRNAs are overexpressed in CTCs and corresponding plasma; miR-21 expression levels highly correlate in CTCs and plasma; and miR-21, miR-146a, and miR-210 are valuable plasma biomarkers for discriminating patients from healthy individuals.

scholarly journals Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1188
Author(s):  
Yanjun Zhou ◽  
Jonas S. Heitmann ◽  
Korbinian N. Kropp ◽  
Martina Hinterleitner ◽  
André Koch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Patients ◽  
Platelet Activation ◽  
Tumor Stage ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Healthy Donors ◽  
A Disintegrin And Metalloproteinase ◽  
Further Development

Tumor progression and metastasis are critically dependent on the tumor microenvironment. A disintegrin and metalloproteinase 17 (ADAM17) is associated with shedding of several substrates involved in tumor progression and known to be expressed by platelets of healthy donors and patients with solid tumors. Here, we report that platelet-derived ADAM17 (pADAM17) is regulated upon platelet activation of breast cancer patients, but not of healthy individuals. The observed downregulation of pADAM17 on platelets of cancer patients correlated with clinical parameters related to tumor progression including tumor stage and the occurrence of metastasis. Our data identify an association between platelet activation, modulation of platelet-derived ADAM17, and metastasis. In conclusion, we demonstrate that further development of pADAM17 as a liquid biomarker is warranted for monitoring disease progression in breast cancer.

The Clinical Utility of Circulating Tumor Cells in Breast Cancer Patients: Detection by a Quantitative Assay of h-MAM Gene Expression

2014 ◽  
Vol 29 (3) ◽  
pp. 268-278 ◽  
Author(s):  
Min Cheng ◽  
Yongyan Chen ◽  
Dehong Zou ◽  
Guodong Shen ◽  
Geng Bian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Detection Rate ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Expression Level ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Epithelial Cancers ◽  
Erbb2 Mrna

The aim of this study was to evaluate tumor markers of molecular abnormalities that display tissue specificity, as to detect circulating tumor cells (CTCs) in breast cancer patients. Quantitative real-time RT-PCR was used to determine h-MAM, BCSG1, CK19, and c-erbB2 mRNA levels in peripheral blood (PB) of breast cancer patients. Results were compared with other epithelial cancers (lung or esophagus cancer), benign breast disease, and healthy individuals. We found that h-MAM mRNA was only detectable in the PB of patients with breast cancer (49 of 65, 75.4%), but not in patients with other epithelial cancers, benign breast disease, or healthy individuals. No significant differences in the expression level and positive detection rate of BCSG1, CK19, and c-erbB2 mRNA were observed between breast cancer and other epithelial cancers. Furthermore, the expression level and positive detection rate of h-MAM mRNA in PB were significantly correlated to the breast cancer pathologic stage (p=0.012 and p=0.015, respectively). Chemotherapy, radiotherapy, or total tumor resection (after 7 days of treatment) resulted in a significant decrease in the expression level of h-MAM mRNA in PB compared to the levels prior to the treatment (p<0.001). Importantly, an increase in h-MAM mRNA expression was detected in patients immediately after surgery, as well as 3 days post-surgery. These results indicate that the quantitative analysis of h-MAM mRNA is a useful tool for detecting CTCs in breast cancer patients, and can have a potential diagnostic utility in early micrometastasis, clinical evaluation of cancer treatment efficacy, and post-treatment monitoring of breast cancer patients.

scholarly journals Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

2020 ◽  
Vol 10 ◽  
Author(s):  
Andrea Feliciano ◽  
Lucila González ◽  
Yoelsis Garcia-Mayea ◽  
Cristina Mir ◽  
Mireia Artola ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Healthy Individuals

Clinical Study of the Serotonin, Melatonin, Estradiol, and Adiponectin Hormones in Women with Breast Cancer in Thi – Qar Governorate -Iraq

2019 ◽  
Vol 10 (01) ◽  
Author(s):  
Hadeel Rashid Faraj1 ◽  
Husam Mohammed Kredy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Control Group ◽  
Serum Estradiol ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Common Cause ◽  
Serum Serotonin ◽  
Apparently Healthy

Objective: Breast cancer is the most widely cancer among women, involving 18% of all female cancers, and worldwide, breast cancer is the fifth most common cause of cancer mortality. The study was designed to determine and compare the levels of Serotonin (ST), Melatonin (MT), Estradiol (E2), and Adiponectin (ADP) Hormones in Breast cancer patients and apparently healthy individuals. Material and Methods: Blood Serotonin (ST), Melatonin (MT), Estradiol(E2), and Adiponectin (ADP) Hormones levels were determined in 85 Breast cancer patients and 55 apparently healthy subjects. Results: The levels of serum Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones were showing significant decrease in Breast cancer patients as compared to control group. ( P ≤ 0.05 ).While the level of serum Estradiol (E2) was showing significant increase in Breast cancer patients as compared to control group.( P ≤ 0.05 ). Conclusion: In Breast cancer patients, we finding decrease in Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones. While we finding increase in Estradiol (E2) in Breast cancer patients as compared to control group.

Sign in / Sign up

Export Citation Format

Share Document